Average Co-Inventor Count = 5.24
ph-index = 15
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Novartis Ag (83 from 3,912 patents)
2. Irm LLC (7 from 151 patents)
3. Ciba-geigy Corporation (4 from 6,850 patents)
4. Schering Aktiengesellschaft (3 from 1,383 patents)
5. Other (2 from 831,952 patents)
6. Novartis Corporation (2 from 166 patents)
7. Elanco Tiergesundheit Ag (2 from 20 patents)
8. Cancer Research Campaign Technology Limited (1 from 61 patents)
9. Novatis Ag (1 from 5 patents)
10. Novarits Ag (1 from 2 patents)
97 patents:
1. 12083101 - Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
2. 10786492 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors
3. 10507201 - Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
4. 10370375 - Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors
5. 10202371 - Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
6. 10189813 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors
7. 10130629 - Pharmaceutical combinations
8. 10059709 - Compounds
9. 9949979 - Use of inhibitors of the activity or function of PI3K
10. 9896444 - Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
11. 9896449 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
12. 9802917 - Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
13. 9795596 - Pharmaceutical diagnostic
14. 9763952 - Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
15. 9751876 - Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension